Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 8/20 | 0.56 |
| ▸ | GNAI3 | P08754 | 7/20 | 0.56 |
| ▸ | GNAI1 | P63096 | 7/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26745710 | 0.98 | GNAO1 (0.59) | GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL27097508 | 0.98 | GNAO1 (0.59) | GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL26511088 | 0.98 | GNAO1 (0.59) | GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL26511089 | 0.98 | GNAO1 (0.59) | GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL26511427 | 0.98 | GNAO1 (0.59) | GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL12064339 | 0.94 | GNAO1 (0.48) | GNAO1GNAI3GNAI1CHRM3 | |
| SCHEMBL12911942 | 0.89 | GNAO1 (0.49) | GNAO1GNAI3GNAI1 | |
| SCHEMBL24261571 | 0.87 | GNAO1 (0.51) | GNAO1GNAI3GNAI1 | |
| SCHEMBL26511527 | 0.87 | GNAO1 (0.51) | GNAO1GNAI3GNAI1 | |
| SCHEMBL12714801 | 0.85 | DRD2 (0.47) | GNAO1GNAI3GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2549991-B1 | FE(III) COMPLEX COMPOUNDS FOR TREATING AND PROPHYLAXIS FOR ANAEMIA SYMPTOMS AND ANAEMIA | VIFOR (INTERNATIONAL) AG (CH) | 2017-11-22 | — | — | EP | disclosed |
| EP-2281818-A1 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-02-09 | — | — | EP | disclosed |
| US-20080261947-A1 | FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. | 2008-10-23 | — | — | US | disclosed |
| US-20080261947-A1 | FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. | 2008-10-23 | — | — | US | disclosed |
| US-7402580-B2 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | disclosed |
| US-7402580-B2 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | disclosed |
| EP-0298982-B1 | PROTECTING GROUPS FOR ORGANIC SYNTHESIS | KING'S COLLEGE LONDON (GB) | 1991-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261947-A1 | FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | MUSK, RNASE1, DPYD | GNAO1 3877/4885GNAI3 3985/4885GNAI1 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.